|Description||LATUDA® is a once-daily oral atypical antipsychotic. In addition to its well-demonstrated efficacy, LATUDA® with its favorable metabolic safety profile may be a solution for unmet medical needs of schizophrenia patients treated with current antipsychotics.|
|Indication||LATUDA® is indicated for the treatment of schizophrenia in adults aged 18 years and over.|
18.5 mg, 37 mg and 74 mg film coated tablets
FDA approved in October 2010
EMA approved in March 2014
Latuda® tablets are registered in UAE and KSA.